JP6091699B2 - 哺乳動物における腟弛緩症又は腟乾燥症を治療するのに用いられる医薬の製造における塩と糖との混合物の使用 - Google Patents
哺乳動物における腟弛緩症又は腟乾燥症を治療するのに用いられる医薬の製造における塩と糖との混合物の使用 Download PDFInfo
- Publication number
- JP6091699B2 JP6091699B2 JP2016505420A JP2016505420A JP6091699B2 JP 6091699 B2 JP6091699 B2 JP 6091699B2 JP 2016505420 A JP2016505420 A JP 2016505420A JP 2016505420 A JP2016505420 A JP 2016505420A JP 6091699 B2 JP6091699 B2 JP 6091699B2
- Authority
- JP
- Japan
- Prior art keywords
- salt
- present
- combination
- composition
- xerostomia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000003839 salts Chemical class 0.000 title claims description 56
- 239000000203 mixture Substances 0.000 title claims description 53
- 241000124008 Mammalia Species 0.000 title claims description 16
- 239000003814 drug Substances 0.000 title claims description 9
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 208000005946 Xerostomia Diseases 0.000 title description 23
- 206010013781 dry mouth Diseases 0.000 title description 23
- 235000002639 sodium chloride Nutrition 0.000 claims description 70
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 21
- 239000008103 glucose Substances 0.000 claims description 19
- 239000011780 sodium chloride Substances 0.000 claims description 15
- 150000002772 monosaccharides Chemical class 0.000 claims description 9
- 238000004140 cleaning Methods 0.000 claims description 7
- 239000007916 tablet composition Substances 0.000 claims description 7
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 5
- 229930091371 Fructose Natural products 0.000 claims description 5
- 239000005715 Fructose Substances 0.000 claims description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 5
- 229930182830 galactose Natural products 0.000 claims description 5
- 230000037303 wrinkles Effects 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 238000012360 testing method Methods 0.000 description 32
- 238000000034 method Methods 0.000 description 21
- 230000000694 effects Effects 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 206010036790 Productive cough Diseases 0.000 description 15
- 210000003802 sputum Anatomy 0.000 description 15
- 208000024794 sputum Diseases 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 12
- 210000003205 muscle Anatomy 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 210000002460 smooth muscle Anatomy 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 7
- 208000014617 hemorrhoid Diseases 0.000 description 7
- 230000001568 sexual effect Effects 0.000 description 7
- 230000003068 static effect Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000011587 new zealand white rabbit Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 206010040954 Skin wrinkling Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- -1 molten salt Chemical class 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000009989 contractile response Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000004071 soot Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- GLDQAMYCGOIJDV-UHFFFAOYSA-N 2,3-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 description 1
- BZISNWGGPWSXTK-UHFFFAOYSA-N 3-hydroxypropyl benzoate Chemical compound OCCCOC(=O)C1=CC=CC=C1 BZISNWGGPWSXTK-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000004172 quinoline yellow Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
実施例1. 本発明の組合せの調製。
1−1. 加工塩の準備
900mgの海塩(新安、韓国、www.nhshinansalt.com)を、加熱器(MS−E104、TOPS Co. Ltd.)を用いることにより850℃〜1000℃で24時間溶融させて、400mgの加工塩を得た。
400mgの精製塩(NaCl、F.W.58.44)を従来から利用可能な会社(SPPO−91701、Duksan company、www.duksan.co.kr)から調達した。
800mgのグルコース(結晶グルコース)を従来から利用可能な会社(Samyang genex Corp.、www.genex.co.kr)から調達した。
上記の工程において準備した400mgの加工塩と800mgのグルコースとを、一緒にして十分に混合して、1200mgの本発明の組合せ(以下「SG1」と称する)を得た。
上記の工程において準備した400mgの精製塩と800mgのグルコースとを、一緒にして十分に混合して、1200mgの本発明の組合せ(以下「SG4」と称する)を得た。
実施例1において調製した、400mgの加工塩と800mgのグルコースとを含む組合せを、2mgのステアリン酸マグネシウムと混合して、打錠(entableting)装置(KT2000、Kumsungkigong)を用いることにより、本発明の腟錠組成物組合せ(以下「SG2」と称する)へと製剤化した。
実施例1において調製した、400mgの精製塩と800mgのグルコースとを含む組合せを、2mgのステアリン酸マグネシウムと混合して、打錠装置(KT2000、Kumsungkigong)を用いることにより、本発明の腟錠組成物組合せ(以下「SG5」と称する)へと製剤化した。
実施例1において調製した400mgの精製塩と800mgのグルコースとを含む組合せ(SG4)を含む腟洗浄溶液組成物を、表1に示す以下の成分を一緒にして48時間撹拌しながら混合することにより調製した(以下「SG3」と称する)。
実施例において調製した本発明の組合せ(SG3)の、ニュージーランド白ウサギにおける腟平滑筋収縮性に対する効果を試験するために、文献(S-J Oh, et al., (2003), Histological and functional aspects of different regions of the rabbit vagina, International Journal of impotence research, 15, pp142-150; N. N. Kim et al., (2004), Effects of ovariectomy and steroid hormones on vaginal smooth muscle contractility, International Journal of Impotence Research, 16, 43-50; A. Giraldi et al., (2001), Joint Award Winning Paper D Jean Francois Ginestie Prize Effects of diabetes on neurotransmission in rat vaginal smooth muscle, International Journal of impotence Research, 13, pp58-66)に開示されている手順に従って器官浴を用いることによって、試験を行った。
本試験(principal test)に先立って、先の文献を考慮してウサギ腟を搬送した後、試験のタイプを決定するために予備試験を行った。
10匹のウサギ(ニュージーランド白ウサギ、Saeron Bio Inc.、Korea、約2.5kg〜3.0kg、1週齢)を、健康状態を調べながら3日間かけて環境に順化させた後、実験に用いた。
本発明の組成物を文献に開示されている器官浴法に従って以下のようにしてウサギ腟組織に投与した:
粘膜(mucose membrane)を除去しておいた筋肉に囲まれたウサギ腟の短冊(1.5mm×10mm)を、混合ガス(95%O2及び5%CO2ガス)で飽和されたクレブス溶液(119mMのNaCl、4.7mMのKCl、1.1mMのMgSO4、1.2mMのKH2PO4、1.5mMのCaCl2、25mMのNaHCO3、10mMのD−グルコース、G1009、Biosesang Corp.、Korea)に37℃で浸漬した。短冊(trip)の末端を固定し、他方の末端をトランスデューサー(モデルFT03;Grass instruments、Quincy、MA、USA)に接続して、20mLのチャンバー(FT03、GRASS Technologies)中でgrassフィジオグラフ(AD instruments、USA)を用いて短冊の等尺性張力を記録した。
異なる条件を用いる様々な予備試験により、以下の手順を確立した。ウサギ腟の短冊をクレブス溶液中、1.2gの静止張力で30分間〜60分間安定化した後、短冊をK+クレブス溶液(43.7mMのNaCl、80mMのKCl、11mMのMgSO4、1.2mMのKH2PO4、1.5mMのCaCl2、18mMのNaHCO3、10mMのD−グルコース、Biosesang Corp.、Korea)中で15分間2回収縮させ、溶液で3回洗浄して安定化させ、その収縮性を求めるための比較試験を行った。
2種類のウサギ腟、即ち、輪型(3mm)及び短冊型(1.5mm×10mm)のウサギ腟を調製し、腟がもっとも安定であり、かつ、安定化の後のK+クレブス溶液の添加に対する収縮性応答がもっとも明白であった、腟の静止張力を選択した。
結果として、短冊型腟組織は、短冊型腟組織よりもK+(80mM)−クレブスに対してより強い収縮性応答を示したので(図2を参照されたい)、短冊型腟組織を、実験における使用のために選択することを確認した。
実施例において調製した腟錠組成物(SG2)を、韓国に住む20歳〜50歳の範囲の、腟弛緩症に罹患している35名の患者と65名の正常女性とからなる100名のボランティアの腟内に1日1回、5日間投与し、本発明の組成物の腟収縮性に対する効果をペリノメーター(peritro9300、Laborie Medical Technologies Canada ULC)を用いることによって調査し、求めた。
実施例において調製した腟挿入錠組成物(SG5)を、韓国に住む20歳〜50歳の範囲の、腟乾燥症に罹患している35名の患者と、65名の正常女性とからなる100名のボランティアに、1日2回、3日間外用投与し、腟乾燥に対する効果を、(A)本発明の組成物による処理前及び(B)処理後に判定した。調査結果を処理後の腟乾燥に応じて5段階、即ち、(1)白帯下の量の大きな減少、(2)白帯下の量のわずかな減少、(3)白帯下の量に変化なし、(4)白帯下の量のわずかな増加、(2)白帯下の量の大きな増加に分類した。
Claims (3)
- 有効成分として(a)海塩又は塩化ナトリウムから選択される塩と(b)グルコース、フルクトース、マンノース又はガラクトースから選択される単糖との組合せを含み、腟弛緩症を治療又は予防するための外用組成物であって、
前記塩と単糖との組合せが、1:1〜1:30(重量比)の混合比で前記塩と前記単糖とが混合されたものである、外用組成物。 - 腟錠組成物又は洗浄液組成物である、請求項1に記載の外用組成物。
- 哺乳動物における腟弛緩症を治療又は予防するのに用いられる医薬の製造における(a)海塩又は塩化ナトリウムから選択される塩と(b)グルコース、フルクトース、マンノース又はガラクトースから選択される単糖との組合せの使用であって、
前記塩と単糖との組合せが、1:1〜1:30(重量比)の混合比で前記塩と前記単糖とが混合されたものである、使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2013-0117300 | 2013-10-01 | ||
KR20130117300 | 2013-10-01 | ||
KR10-2014-0053161 | 2014-05-02 | ||
KR1020140053161A KR101470282B1 (ko) | 2013-10-01 | 2014-05-02 | 소금 및 당의 조합물을 유효성분으로 함유하는 질이완증 또는 질건조증 예방 및 치료용 약학 조성물 및 이의 용도 |
PCT/KR2014/008180 WO2015050324A1 (en) | 2013-10-01 | 2014-09-02 | A use of the mixture of a salt and sugar in the manufacture of a medicament employed for treating lax vegina syndrome or colpoxerosis disease in a mammal |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016515574A JP2016515574A (ja) | 2016-05-30 |
JP6091699B2 true JP6091699B2 (ja) | 2017-03-08 |
Family
ID=52678056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016505420A Active JP6091699B2 (ja) | 2013-10-01 | 2014-09-02 | 哺乳動物における腟弛緩症又は腟乾燥症を治療するのに用いられる医薬の製造における塩と糖との混合物の使用 |
Country Status (15)
Country | Link |
---|---|
US (4) | US20150342987A1 (ja) |
EP (1) | EP2978435B1 (ja) |
JP (1) | JP6091699B2 (ja) |
KR (1) | KR101470282B1 (ja) |
CN (1) | CN104884070B (ja) |
AU (1) | AU2014330225B2 (ja) |
BR (1) | BR112015015370B1 (ja) |
CA (1) | CA2896936C (ja) |
HK (1) | HK1210412A1 (ja) |
MX (1) | MX2015009485A (ja) |
MY (1) | MY175936A (ja) |
NZ (1) | NZ709010A (ja) |
PH (1) | PH12015501458A1 (ja) |
RU (1) | RU2613714C2 (ja) |
WO (1) | WO2015050324A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101470282B1 (ko) | 2013-10-01 | 2014-12-05 | 최원석 | 소금 및 당의 조합물을 유효성분으로 함유하는 질이완증 또는 질건조증 예방 및 치료용 약학 조성물 및 이의 용도 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2256365A1 (en) * | 1996-05-22 | 1997-11-27 | Diversified Pharmaceuticals, Inc. | Compositions, methods and devices for the transdermal delivery of drugs |
KR20010029068A (ko) * | 1999-09-29 | 2001-04-06 | 강권중 | 죽염과 운모를 유효성분으로 함유하는 질정제 |
CN100389763C (zh) * | 2004-02-10 | 2008-05-28 | 周世兰 | 改善妇***道酸、湿性的乳酸、甘油制剂 |
US20080286384A1 (en) * | 2004-09-15 | 2008-11-20 | Renee Reichert | Topical Wound Care Product Containing Hyssop |
US7619008B2 (en) * | 2004-11-12 | 2009-11-17 | Kimberly-Clark Worldwide, Inc. | Xylitol for treatment of vaginal infections |
US8703198B2 (en) * | 2005-03-02 | 2014-04-22 | Aquatrove Biosciences | Water-based personal moisturizers and lubricants, in particular vaginal lubricants, and uses thereof |
WO2006110024A1 (en) * | 2005-04-11 | 2006-10-19 | R & H Minerals B.V. | Salt product, method for manufacture and use thereof |
CA2609754C (en) * | 2005-04-27 | 2012-01-10 | Shenzhen Phlora Biotechnology Limited | Compositions of benzoic acid and saccharides for regulating and maintaining bacterial flora and acidity in the vagina |
CN1994274A (zh) * | 2006-01-04 | 2007-07-11 | 吴天祥 | 仿生***化妆品 |
EP2099309A4 (en) * | 2006-01-24 | 2014-04-30 | Fjell & Fjord Mat As | COMPOSITION COMPRISING SUGAR AND SALT FOR THE TREATMENT OF MEAT |
US8765819B2 (en) * | 2009-10-08 | 2014-07-01 | Zhongming Zeng | Composition comprising benzoic acid in combination with organic acid preservatives as active ingredients and the use thereof |
KR101133723B1 (ko) * | 2009-10-19 | 2012-04-09 | 최원석 | 소금 및 당을 유효성분으로 함유하는 질염 예방 및 치료용 조성물 및 이의 용도 |
RU2428173C1 (ru) * | 2010-06-03 | 2011-09-10 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Фармацевтическая композиция для лечения заболеваний нижнего отдела мочеполовой системы |
ES2896968T3 (es) * | 2010-11-12 | 2022-02-28 | The Univ Of Utah Research Foundation | Dispositivos intravaginales para el suministro controlado de lubricantes |
ES2390033B1 (es) * | 2010-11-30 | 2013-10-31 | Lipotec S.A. | Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas. |
CN102240260B (zh) * | 2011-05-17 | 2012-05-23 | 山东省医疗器械研究所 | 一种治疗***干涩症的药物及其制备方法 |
KR101470282B1 (ko) | 2013-10-01 | 2014-12-05 | 최원석 | 소금 및 당의 조합물을 유효성분으로 함유하는 질이완증 또는 질건조증 예방 및 치료용 약학 조성물 및 이의 용도 |
-
2014
- 2014-05-02 KR KR1020140053161A patent/KR101470282B1/ko active IP Right Review Request
- 2014-09-02 CA CA2896936A patent/CA2896936C/en active Active
- 2014-09-02 WO PCT/KR2014/008180 patent/WO2015050324A1/en active Application Filing
- 2014-09-02 MY MYPI2015701940A patent/MY175936A/en unknown
- 2014-09-02 CN CN201480004031.2A patent/CN104884070B/zh active Active
- 2014-09-02 US US14/653,853 patent/US20150342987A1/en not_active Abandoned
- 2014-09-02 NZ NZ709010A patent/NZ709010A/en unknown
- 2014-09-02 AU AU2014330225A patent/AU2014330225B2/en active Active
- 2014-09-02 RU RU2015126018A patent/RU2613714C2/ru active
- 2014-09-02 MX MX2015009485A patent/MX2015009485A/es active IP Right Grant
- 2014-09-02 BR BR112015015370-4A patent/BR112015015370B1/pt active IP Right Grant
- 2014-09-02 EP EP14850829.4A patent/EP2978435B1/en active Active
- 2014-09-02 JP JP2016505420A patent/JP6091699B2/ja active Active
-
2015
- 2015-06-24 PH PH12015501458A patent/PH12015501458A1/en unknown
- 2015-11-11 HK HK15111126.7A patent/HK1210412A1/zh unknown
-
2016
- 2016-09-11 US US15/262,000 patent/US9827267B2/en active Active
-
2017
- 2017-08-29 US US15/688,872 patent/US9867850B2/en active Active
- 2017-08-29 US US15/688,871 patent/US9925216B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2016515574A (ja) | 2016-05-30 |
US20170354678A1 (en) | 2017-12-14 |
AU2014330225A1 (en) | 2015-07-02 |
BR112015015370A2 (pt) | 2017-07-11 |
CN104884070B (zh) | 2016-08-31 |
US20150342987A1 (en) | 2015-12-03 |
NZ709010A (en) | 2017-05-26 |
US9867850B2 (en) | 2018-01-16 |
CN104884070A (zh) | 2015-09-02 |
EP2978435A4 (en) | 2017-01-04 |
PH12015501458B1 (en) | 2015-09-21 |
RU2015126018A (ru) | 2017-01-10 |
PH12015501458A1 (en) | 2015-09-21 |
BR112015015370B1 (pt) | 2020-11-10 |
CA2896936A1 (en) | 2015-04-09 |
RU2613714C2 (ru) | 2017-03-21 |
US20160375053A1 (en) | 2016-12-29 |
US9925216B2 (en) | 2018-03-27 |
HK1210412A1 (zh) | 2016-04-22 |
KR101470282B1 (ko) | 2014-12-05 |
EP2978435B1 (en) | 2019-03-13 |
EP2978435A1 (en) | 2016-02-03 |
AU2014330225B2 (en) | 2016-11-17 |
WO2015050324A1 (en) | 2015-04-09 |
MX2015009485A (es) | 2015-11-16 |
US9827267B2 (en) | 2017-11-28 |
MY175936A (en) | 2020-07-15 |
US20170354679A1 (en) | 2017-12-14 |
CA2896936C (en) | 2018-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11458190B2 (en) | Mussel adhesive protein product and use thereof for treating mucosal inflammation | |
CN107456509B (zh) | 一种用于女性***预防、保健以及治疗妇科生殖道炎症的外用生物制剂以及制备方法 | |
KR101599447B1 (ko) | 조성물 및 항문 치열 치료에서의 그 용도 | |
JP6091699B2 (ja) | 哺乳動物における腟弛緩症又は腟乾燥症を治療するのに用いられる医薬の製造における塩と糖との混合物の使用 | |
CN103721138B (zh) | 一种治疗酒糟鼻的中药外用制剂及其制备方法 | |
CN104623457A (zh) | 缩阴排毒祛斑凝胶剂及其制备方法 | |
Brumley | A Text-book of the Diseases of the Small Domestic Animals | |
Byford | The Practice of medicine and surgery | |
Walsham | Surgery: its theory and practice | |
CN105030920A (zh) | 一种治疗口腔溃疡和喉病的中药组合物 | |
Walters | SURGICAL MEMORANDA. | |
Sprays et al. | 414 Tim romAL] THE ANNUAL MUSEUM.[AUG. 25, 1894. portance, in gradually straightening knock-knee with splints-there is a great tendency lor the ligaments to yield as well as the bones, a flail-like joint resulting, whereas in osteoclasis the bone alone gives way. My hands are the | |
Saunders | Canine medicine and surgery | |
Williams | The principles and practice of veterinary surgery | |
Cruris et al. | Progress of 3 ledical Science. | |
GIC | AN EPITOME OF CURRENT MEDICAL LITERATURE | |
Howe | Emergencies and how to treat them | |
DOCK | UNDER THE CHARGE OF WILLIAM OSLER, MD, PROFESSOR OF MEDICINE IN THE JOHNS HOPKINS UNIVERSITY, BALTIMORE, MARYLAND, AND | |
VIII | the most prominent points contained in the Reports of the respective com | |
Goelet | tl, 0j. ln^ ure the party suing. The Supreme Court of Ohio | |
COPAIBA | 1108', T, F^. P,] ROYAL MEDICAL AND CHIRURGICAL SOCIETY.[Nov. 17, 1894. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20160310 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160322 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160607 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160809 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160912 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161101 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170119 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170131 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170207 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6091699 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |